Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Aerpio Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib

            Therapeutic Area: Ophthalmology Product Name: AKB-9778

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 24, 2020

            Details:

            Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Quantum Leap Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 27, 2020

            Details:

            The collaboration aims at evaluating razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB004

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gossamer Bio

            Deal Size: $105.0 million Upfront Cash: $15.0 million

            Deal Type: Licensing Agreement May 12, 2020

            Details:

            The renegotiated licensing deal is intended to place Gossamer Bio in a better position to progress GB004, and in addition, is designed to facilitate the further development of each company’s respective pipelines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib,Prostaglandin

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2020

            Details:

            The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib,Prostaglandin

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.